Jan Keltjens

Jan Keltjens currently serves as Chairman of the Board of Directors of JenaValve Technologies and Vicentra b.v. Both are late-stage startups focused on Structural Hearth respectively Diabetes Management. Besides those, he holds a number of Board roles at high-tech medical device companies. He is also associated with some venture capital funds. This includes a.o. INKEF (Amsterdam), at which he is a member of the Advisory Board, as well as Brightlands Venture Partners, where he chairs the Board of Directors of several funds.

Prior to this, Jan served as Chairman of the Board at NightBalance (acquired by Philips in 2018). Before that, he was the chief executive officer of Sapiens Steering Brain Stimulation (acquired by Medtronic in 2014), chairman and chief executive officer of Endosense SA (acquired by St Jude Medical in 2013), executive chairman of Surpass Medical ltd. (acquired by Stryker Corporation in 2012), as well as president and chief executive officer of AngioDynamics Inc. (NASDAQ; ANGO, 2009 – 2011) and CryoCath Technologies Inc. (TSX; CYT, 2007- until its acquisition by Medtronic in 2009).

From 2000 to 2007, he served as Worldwide General Manager of Cordis Neurovascular, a Johnson & Johnson company. He joined Cordis in 1995 as Vice President and Managing Director responsible for international operations, as well as R&D. Within Cordis, he also served in a number of senior leadership positions in European and Global Marketing. Prior to this, Jan led R&D departments at Unilever and was Managing Director of a group of high-tech service providers.

Mr. Keltjens holds a Master’s degree in Applied Physics from Technical University Eindhoven, the Netherlands.